Cargando…

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping

Molecular signatures have been suggested as biomarkers to classify pancreatic ductal adenocarcinoma (PDAC) into two, three, four or five subtypes. Since the robustness of existing signatures is controversial, we performed a systematic evaluation of four established signatures for PDAC stratification...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lautizi, Manuela, Baumbach, Jan, Weichert, Wilko, Steiger, Katja, List, Markus, Pfarr, Nicole, Kacprowski, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Cancer Computational Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575186/ https://www.ncbi.nlm.nih.gov/pubmed/36267208 http://dx.doi.org/10.1093/narcan/zcac030

Ejemplares similares

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
por: Kaissis, Georgios, et al.
Publicado: (2019)

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes
por: Schlitter, Anna Melissa, et al.
Publicado: (2017)

Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma
por: Kaissis, Georgios A., et al.
Publicado: (2020)

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
por: Sun, Na, et al.
Publicado: (2021)

Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters
por: Kaissis, Georgios A., et al.
Publicado: (2020)

A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging
por: Kaissis, Georgios, et al.
Publicado: (2019)

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma
por: Stenzinger, Albrecht, et al.
Publicado: (2013)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma
por: Seifert, Adrian M., et al.
Publicado: (2020)

MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2022)

Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
por: Stögbauer, Fabian, et al.
Publicado: (2023)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
por: Croft, Wayne, et al.
Publicado: (2023)

Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Mahajan, Ujjwal Mukund, et al.
Publicado: (2021)

Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma
por: Yu, Xiang, et al.
Publicado: (2017)

Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy
por: Collisson, Eric A., et al.
Publicado: (2011)

Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
por: Roy, Shikha, et al.
Publicado: (2021)

[(18)F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
por: Harder, Felix N., et al.
Publicado: (2021)

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
por: Noll, Elisa M., et al.
Publicado: (2016)

Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas
por: Fujiwara, Sho, et al.
Publicado: (2019)

Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
por: Zhang, Aibin, et al.
Publicado: (2017)

Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Candido, Juliana B., et al.
Publicado: (2021)

Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer
por: Grosser, Bianca, et al.
Publicado: (2020)

Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma
por: Fan, Yuhui, et al.
Publicado: (2020)

Network-based approaches for modeling disease regulation and progression
por: Galindez, Gihanna, et al.
Publicado: (2022)

Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity
por: Schmuck, Rosa B., et al.
Publicado: (2015)

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
por: Cremin, Carol, et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
por: de Santiago, Ines, et al.
Publicado: (2019)

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
por: Espiau-Romera, Pilar, et al.
Publicado: (2020)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
por: Lu, Haizhen, et al.
Publicado: (2017)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: He, Chaobin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gakof434ae0vs8cgdbab1kqedu